Login to Your Account

Clinic Roundup

Thursday, October 24, 2013

• Halozyme Therapeutics Inc., of San Diego, Calif., began a Phase Ib/II trial of PEGPH20 in combination with FOLFIRINOX chemotherapy compared to FOLFIRINOX alone in metastatic pancreatic adenocarcinoma. The trial will enroll about 144 patients. The initial Phase Ib portion of the trial will confirm the optimal dose of PEGPH20 for the Phase II potion, which will evaluate overall survival. Secondary endpoints include progression-free survival, objective tumor response, and adverse events.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription